Tina deVries's most recent trade in RVL Pharmaceuticals plc was a trade of 5,447 Ordinary Shares done at an average price of $1.4 . Disclosure was reported to the exchange on May 18, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| RVL Pharmaceuticals plc | Tina deVries | EVP, Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.40 per share. | 18 May 2022 | 5,447 | 136,141 (0%) | 0% | 1.4 | 7,626 | Ordinary Shares |
| RVL Pharmaceuticals plc | Tina deVries | EVP, Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.13 per share. | 24 Jan 2022 | 9,607 | 141,588 (0%) | 0% | 1.1 | 10,856 | Ordinary Shares |
| RVL Pharmaceuticals plc | Tina deVries | EVP, Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Nov 2021 | 216,944 | 216,944 | - | - | Share Option (Right to Buy) | |
| RVL Pharmaceuticals plc | Tina deVries | EVP, Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.12 per share. | 18 May 2021 | 6,467 | 151,195 (0%) | 0% | 3.1 | 20,177 | Ordinary Shares |
| RVL Pharmaceuticals plc | Tina deVries | EVP, Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.46 per share. | 24 Jan 2021 | 9,597 | 157,662 (0%) | 0% | 4.5 | 42,803 | Ordinary Shares |